Answers are grounded in this paper and cite their sources.
The Cxbladder Monitor test significantly outperforms current Food and Drug Administration-approved urine-based monitoring tests, as well as cytology, in a large representative population undergoing surveillance for recurrent UC. This supports using Cxbladder Monitor as a confirmatory negative adjunct to cystoscopy or to justify postponing cystoscopic investigations in patients with a low risk of recurrence.
No takes yet. Share an insight, caveat, or question.
Lotan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: